CG
PCVX icon

Cutler Group’s Vaxcyte PCVX Stock Holding History

Cutler Group’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$4K Buy
6,500
+1,500
+30% +$104K ﹤0.01% 1642
2023
Q4 		$78K Buy
+5,000
New +$260K 0.01% 1183
2023
Q1 		– Sell
-6,500
Closed -$107K – 4481
2022
Q4 		$107K Buy
+6,500
New +$255K 0.01% 1123

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Cutler Group's PCVX Position: Q2 2023 in Review

Cutler Group sold out of Vaxcyte (PCVX) in Q2 2023, closing a stake of 3,000 shares — an estimated $112K sold.

Cutler Group first reported a position in PCVX in Q1 2023 and held it in 1 quarter. The position peaked at $112K in Q1 2023. 197 funds tracked by Wall St. Rank hold PCVX as of Q2 2023.

  • Cutler Group reported no remaining Vaxcyte position as of Q2 2023 after selling out during the quarter.
  • Cutler Group sold 3,000 Vaxcyte shares in Q2 2023, an estimated $112K.
  • Cutler Group first reported a position in Vaxcyte in Q1 2023 and held it in 1 quarter.
  • Cutler Group's Vaxcyte position peaked at $112K in Q1 2023.
  • 197 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2023.

Based on Cutler Group's 13F filing for Q2 2023, filed 18 Jul 2023.